Hepatitis C: The Story of a Long Journey through First, Second, and Third Generation NS3/4A Peptidomimetic Inhibitors. What Did We Learn?
SD Martino, GL Petri, M De Rosa - Journal of Medicinal Chemistry, 2024 - ACS Publications
Hepatitis C viral (HCV) infection is the leading cause of liver failure and still represents a
global health burden. Over the past decade, great advancements made HCV curable, and …
global health burden. Over the past decade, great advancements made HCV curable, and …
The discovery of conformationally constrained bicyclic peptidomimetics as potent Hepatitis C NS5A inhibitors
WM Kazmierski, N Miriyala, DK Johnson… - ACS Medicinal …, 2021 - ACS Publications
HCV NS5A inhibitors are the backbone of directly acting antiviral treatments against the
hepatitis C virus (HCV). While these therapies are generally highly curative, they are less …
hepatitis C virus (HCV). While these therapies are generally highly curative, they are less …
Novel peptidomimetic hepatitis C virus NS3/4A protease inhibitors spanning the P2–P1′ region
AK Lampa, SM Bergman, SS Gustafsson… - ACS Medicinal …, 2014 - ACS Publications
Herein, novel hepatitis C virus NS3/4A protease inhibitors based on a P2
pyrimidinyloxyphenylglycine in combination with various regioisomers of an aryl acyl …
pyrimidinyloxyphenylglycine in combination with various regioisomers of an aryl acyl …
HCV NS3/4A protease inhibitors and the road to effective direct-acting antiviral therapies
N Tremblay, AY Park, D Lamarre - Hepatitis C Virus II: Infection and …, 2016 - Springer
Hepatitis C virus (HCV) currently infects over 185 million individuals around the world. Its
persistence causes infected individuals to enter a chronic phase where their condition can …
persistence causes infected individuals to enter a chronic phase where their condition can …
Inhibitors of the Hepatitis C Virus NS3 Protease with Basic Amine Functionality at the P3-Amino Acid N-Terminus: Discovery and Optimization of a New Series of P2 …
S Harper, M Ferrara, B Crescenzi… - Journal of medicinal …, 2009 - ACS Publications
In a follow-up to our recent disclosure of P2− P4 macrocyclic inhibitors of the hepatitis C
virus (HCV) NS3 protease (eg, 1, Chart 1), we report a new but related compound series …
virus (HCV) NS3 protease (eg, 1, Chart 1), we report a new but related compound series …
Pan-NS3 protease inhibitors of hepatitis C virus based on an R3-elongated pyrazinone scaffold
AK Belfrage, E Abdurakhmanov, E Åkerblom… - European Journal of …, 2018 - Elsevier
Herein, we present the design and synthesis of 2 (1H)-pyrazinone based HCV NS3 protease
inhibitors and show that elongated R 3 urea substituents were associated with increased …
inhibitors and show that elongated R 3 urea substituents were associated with increased …
Peptide-based inhibitors of hepatitis C virus full-length NS3 (protease-helicase/NTPase): model compounds towards small molecule inhibitors
K Oscarsson, A Poliakov, S Oscarson… - Bioorganic & medicinal …, 2003 - Elsevier
From l-α-aminobutyric acid (Abu) a set of electrophilic and non-electrophilic replacements
for the P1 cysteine of substrate and product inhibitors of hepatitis C virus full-length NS3 …
for the P1 cysteine of substrate and product inhibitors of hepatitis C virus full-length NS3 …
1H-Imidazole-2,5-Dicarboxamides as NS4A Peptidomimetics: Identification of a New Approach to Inhibit HCV-NS3 Protease
The nonstructural (NS) protein NS3/4A protease is a critical factor for hepatitis C virus (HCV)
maturation that requires activation by NS4A. Synthetic peptide mutants of NS4A were found …
maturation that requires activation by NS4A. Synthetic peptide mutants of NS4A were found …
Discovery of novel potent and selective dipeptide hepatitis C virus NS3/4A serine protease inhibitors
P Raboisson, TI Lin, H de Kock, S Vendeville… - Bioorganic & medicinal …, 2008 - Elsevier
Starting from the previously reported HCV NS3/4A protease inhibitor BILN 2061 (1), we have
used a fast-follower approach to identify a novel series of HCV NS3/4A protease inhibitors in …
used a fast-follower approach to identify a novel series of HCV NS3/4A protease inhibitors in …
The changing face of hepatitis C: recent advances on HCV inhibitors targeting NS5A
D Rai, L Wang, X Jiang, P Zhan, H Jia… - Current Medicinal …, 2015 - ingentaconnect.com
Current treatment for HCV infections consists of approved direct acting antivirals (DAAs), viz.
the protease inhibitors (boceprevir, telaprevir, and simeprevir), NS5B polymerase inhibitors …
the protease inhibitors (boceprevir, telaprevir, and simeprevir), NS5B polymerase inhibitors …